Shukang Submits IPO Prospectus: Pioneering Digital Therapeutics for Chronic Disease Rehabilitation with Global First-Mover Advantage and Insurance Reimbursement Pathways
Data shows that China currently has approximately 50,000 rehabilitation therapists, with only 3.57 therapists per 100,000 people. Therefore, it is an urgent priority to establish a mature training system for rehabilitation therapists while improving their work efficiency to meet the substantial demand for rehabilitation services among the population.
Digital Exercise Rehabilitation for Chronic Diseases, Helping Therapists ThroughThe World's FirstDigital Software for Exercise Prescription"Shukang App"Manage patients by enabling them to safely complete exercise prescriptions using only wearable smart devices, thereby improving adherence and facilitating medication reduction under physician guidance.
Low-cost and high-efficiency, significantly improving therapists’ efficiency in patient management, enabling large-scale implementation to help more patients with chronic diseases.“Digital Exercise Rehabilitation Program”Comprehensive medical institutions provide multidisciplinary coverage, while primary care facilities focus on chronic disease rehabilitation and treatment, thereby optimizing the rehabilitation service delivery process and improving patients' quality of life.
On Monday, March 18, at 19:30, the 46th session of VCBeat Select New Product Showcase will feature Dong Lei, Senior Medical Advisor at Shukang, and Liu Jia, Marketing Director at Shukang, who will present the “Digital Exercise Rehabilitation for Chronic Diseases” project.
The image shows “ShuKang APP,” a software product that provides exercise prescriptions for the rehabilitation treatment of chronic diseases such as cardiovascular disease.
1Shukang Pro
· Personalized Prescription
· Video Guide
· Real-time Monitoring
· Intelligent Optimization
2Shukang Doctor Pro
· Thousands of Exercise Library, Intelligent Personalized Exercise Prescription
· Monitor Exercise Data, Intelligent Processing Recommendations
· Flexible Follow-up Plans, Customized Questionnaire Scales
“Shukang APP” is the first “digital therapeutic” approved by the NMPA in China.According to the International Digital Therapeutics Alliance’s detailed classification criteria for digital health, the Shukang App is the first digital therapeutic in China that can be prescribed as a standalone application. It was the first to be applied to cardiac rehabilitation for heart failure patients in the United States, has obtained FDA clearance as a Class II medical device, and has successfully established commercial insurance reimbursement channels, securing payment from commercial insurers.
Scan the QR code on the poster to add our assistant and reserve your spot for the live broadcast.
Dong Lei
Shukang Senior Medical Consultant
Ph.D. in Clinical Medicine, Xiangya Hospital of Central South University
China's First Ph.D. in Cardiac Rehabilitation
Liu Jia
ShuKang Marketing Director
Former executive at healthcare institutions and pharmaceutical companies, with extensive experience in market operations and well-versed in medical compliance policies.
RECOVERY PLUS
RECOVERY PLUS is the developer of the Shukang APP, a “digital therapeutics” platform. It is dedicated to providing remote intelligent rehabilitation services through digital therapeutics for patients with chronic diseases (including advanced-stage severe conditions such as cardiovascular diseases and cancer), chronic pain, as well as individuals seeking to enhance brain development and delay cognitive decline.
After years of R&D and clinical research, its independently developed “ShuKang” App was approved by the National Medical Products Administration (NMPA) in November 2020, obtaining a Class II medical device certificate and emerging as a pioneer in “digital therapeutics.” The international version of “ShuKang” has been adopted as a first-line treatment for cardiac rehabilitation in heart failure patients at prestigious U.S. hospitals. It has secured FDA clearance as a Class II medical device and successfully established reimbursement channels with commercial insurers, achieving coverage through private insurance payments.
“Artery Select New Product Debut” is a live-streaming program under “Artery Select” designed to support medical enterprises in launching innovative products. The program’s mission is to facilitate the milestone launch of every innovative medical product.
Scan the QR code below to contact the assistant and schedule a live stream.
(If already added, please proactively consult the assistant)
